USFDA approves Glenmark's acidity treatment generic drug

13 Jun 2024 , 10:20 AM

Glenmark received approval from the US FDA to market a generic drug for stomach acid conditions. The approval is for Esomeprazole Magnesium delayed-release capsules. Glenmark’s product is a generic version of Haleon US Holdings LLC’s Nexium.

At the time of writing on June 13, 2024 at 10:20 am, shares of Glenmark Pharma were trading at ₹1212, which is a 0.80% gain than the previous close. The stock has gained 86% gain than the previous close, and 41% since the beginning of the year.

Glenmark Pharmaceuticals Limited, an Indian multinational pharmaceutical company, is headquartered in Mumbai.

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/